• Mashup Score: 2
    JUMP: update on ruxolitinib for myelofibrosis - 3 year(s) ago

    Francesco Passamonti, MD, University of Insubria, Varese, Italy, talks on the findings of an analysis of data from the JUMP…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Evaluating the activity of ruxolitinib in four patient risk categories based on the DIPSS Francesco Passamonti (@Uni_Insubria) discusses an analysis of data from the JUMP trial of ruxolitinib for #Myelofibrosis: https://t.co/4Q5o0QV3YF @SocietyofHemOnc #SOHO2021 #HemOnc #MPNsm

  • Mashup Score: 2
    How do you approach the treatment of untreated DLBCL? - 3 year(s) ago

    During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the Lymphoma Hub was pleased to speak to Jason Westin, MD Anderson Cancer Center, Houston, US. We asked, How do you approach the treatment of untreated diffuse large B-cell lymphoma (DLBCL)?

    Source: lymphomahub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of lymphomahub
      lymphomahub

      👀 During #SOHO2021, the @lymphomahub was pleased to speak to @Lymphoma_Doc, @MDAndersonNews. We asked, How do you approach the treatment of untreated diffuse large B-cell lymphoma (#DLBCL)? 👉 https://t.co/OjiqpA1cpg 👈 #lymsm #lymphoma https://t.co/8Kw1ugCwwW

  • Mashup Score: 6
    New MPN clinical trials & drugs in 2021 - 3 year(s) ago

    Prithviraj Bose, MD, The University of Texas MD Anderson Cancer, Houston, TX, comments on topical clinical trials investigating the treatment…

    Source: VJHemOnc
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      💊New MPN clinical trials & drugs in 2021💊 w/ @bose_prithviraj of @MDAndersonNews: https://t.co/kqSqBNHLN9 @SocietyofHemOnc #SOHO2021 #HemOnc #MPNsm #CTSM #TrialUpdates #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM

  • Mashup Score: 2
    How could new immunotherapy modalities in AML change current practice? - 3 year(s) ago

    During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Amir Fathi, Massachusetts General Hospital, Boston, US. We asked, How could new immunotherapy modalities in acute myeloid leukemia (AML) change current practice?

    Source: aml-hub.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of AML_Hub
      AML_Hub

      🩺 During #SOHO2021, the @AML_Hub spoke to Amir Fathi, @MassGeneralNewsl. We asked, How could new immunotherapy modalities in #AML change current practice? 👉 https://t.co/RmHcpd8YVs 👈 #leusm #leukemia #AMLsm https://t.co/fJsv45Km4m

  • Mashup Score: 0
    Racial, Social Disparities Linked With T-Cell Lymphoma Outcomes - 3 year(s) ago

    Existing racial and socioeconomic disparities among patients with T-cell non-Hodgkin lymphoma continue to lead to obstacles with access for newly available treatment options.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      One of the main disparities among both adults and children with T-cell lymphoma was that ethnic and racial minorities had a worse median overall survival compared with other patients @WinshipAtEmory @MaryjoLechowicz @SocietyofHemOnc #SOHO2021 #leusm #lymsm https://t.co/8j785M1dmL https://t.co/AF7qqXaSq8

  • Mashup Score: 0
    Ruxolitinib Represents a Key Clinical Tool in Polycythemia Vera Paradigm - 3 year(s) ago

    The JAK1/JAK2 inhibitor ruxolitinib has several clinical uses in the treatment of patients with polycythemia vera and plays an especially important role in adult patients who have had an inadequate response to hydroxyurea.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      The JAK1/JAK2 inhibitor ruxolitinib has several clinical uses in the treatment of pts w/ polycythemia vera and plays an important role in patients who have had an inadequate response to hydroxyurea. @DukeHealth @rizzi003 @SocietyofHemOnc #SOHO2021 #leusm https://t.co/WhzB4CPeXv

Load More